Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novel Biologics In US Might Not Start Getting Suffixes Until August

Executive Summary

FDA has cleared four novel biologics without a suffix despite finalizing nonproprietary naming guidance; the agency requests sponsors submit proposed suffixes at the time a BLA is submitted.

Advertisement

Related Content

Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles
Novo Nordisk Gets Approval For Hemophilia B Treatment Sans Postmarketing Requirements
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
Drug Development, Not Conflicts, Dominates Gottlieb's Confirmation Hearing
Where’s The Suffix? Valeant’s Siliq Approved Without Four-Letter Identifier
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel